Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 3
1998 13
1999 19
2000 14
2001 13
2002 11
2003 20
2004 23
2005 44
2006 48
2007 49
2008 59
2009 80
2010 86
2011 95
2012 131
2013 184
2014 198
2015 223
2016 238
2017 228
2018 195
2019 155
2020 11
Text availability
Article attribute
Article type
Publication date

Search Results

1,899 results
Results by year
Filters applied: . Clear all
Page 1
PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation.
Keppler-Noreuil KM, Rios JJ, Parker VE, Semple RK, Lindhurst MJ, Sapp JC, Alomari A, Ezaki M, Dobyns W, Biesecker LG. Keppler-Noreuil KM, et al. Am J Med Genet A. 2015 Feb;167A(2):287-95. doi: 10.1002/ajmg.a.36836. Epub 2014 Dec 31. Am J Med Genet A. 2015. PMID: 25557259 Free PMC article.
[PIK3CA-related overgrowth syndrome (PROS)].
Venot Q, Canaud G. Venot Q, et al. Nephrol Ther. 2017 Apr;13 Suppl 1:S155-S156. doi: 10.1016/j.nephro.2017.02.004. Nephrol Ther. 2017. PMID: 28577738 Review. French.
PI3Kδ and primary immunodeficiencies.
Lucas CL, Chandra A, Nejentsev S, Condliffe AM, Okkenhaug K. Lucas CL, et al. Nat Rev Immunol. 2016 Nov;16(11):702-714. doi: 10.1038/nri.2016.93. Epub 2016 Sep 12. Nat Rev Immunol. 2016. PMID: 27616589 Free PMC article. Review.
Metabolic Determinants of Sensitivity to Phosphatidylinositol 3-Kinase Pathway Inhibitor in Small-Cell Lung Carcinoma.
Makinoshima H, Umemura S, Suzuki A, Nakanishi H, Maruyama A, Udagawa H, Mimaki S, Matsumoto S, Niho S, Ishii G, Tsuboi M, Ochiai A, Esumi H, Sasaki T, Goto K, Tsuchihara K. Makinoshima H, et al. Cancer Res. 2018 May 1;78(9):2179-2190. doi: 10.1158/0008-5472.CAN-17-2109. Epub 2018 Feb 28. Cancer Res. 2018. PMID: 29490947 Free article.
Cancer-Associated PIK3CA Mutations in Overgrowth Disorders.
Madsen RR, Vanhaesebroeck B, Semple RK. Madsen RR, et al. Trends Mol Med. 2018 Oct;24(10):856-870. doi: 10.1016/j.molmed.2018.08.003. Epub 2018 Sep 6. Trends Mol Med. 2018. PMID: 30197175 Free PMC article. Review.
CLOVES syndrome: review of a PIK3CA-related overgrowth spectrum (PROS).
Martinez-Lopez A, Blasco-Morente G, Perez-Lopez I, Herrera-Garcia JD, Luque-Valenzuela M, Sanchez-Cano D, Lopez-Gutierrez JC, Ruiz-Villaverde R, Tercedor-Sanchez J. Martinez-Lopez A, et al. Clin Genet. 2017 Jan;91(1):14-21. doi: 10.1111/cge.12832. Epub 2016 Aug 3. Clin Genet. 2017. PMID: 27426476 Review.
The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer.
Zeng SX, Zhu Y, Ma AH, Yu W, Zhang H, Lin TY, Shi W, Tepper CG, Henderson PT, Airhart S, Guo JM, Xu CL, deVere White RW, Pan CX. Zeng SX, et al. Clin Cancer Res. 2017 Nov 1;23(21):6580-6591. doi: 10.1158/1078-0432.CCR-17-0033. Epub 2017 Aug 14. Clin Cancer Res. 2017. PMID: 28808038 Free PMC article.
Germline-activating mutations in PIK3CD compromise B cell development and function.
Avery DT, Kane A, Nguyen T, Lau A, Nguyen A, Lenthall H, Payne K, Shi W, Brigden H, French E, Bier J, Hermes JR, Zahra D, Sewell WA, Butt D, Elliott M, Boztug K, Meyts I, Choo S, Hsu P, Wong M, Berglund LJ, Gray P, O'Sullivan M, Cole T, Holland SM, Ma CS, Burkhart C, Corcoran LM, Phan TG, Brink R, Uzel G, Deenick EK, Tangye SG. Avery DT, et al. J Exp Med. 2018 Aug 6;215(8):2073-2095. doi: 10.1084/jem.20180010. Epub 2018 Jul 17. J Exp Med. 2018. PMID: 30018075 Free PMC article.
1,899 results
Jump to page